An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery
Lee F Willoughby, Tanja Schlosser, Samuel A Manning, John P Parisot, Ian P Street, Helena E Richardson, Patrick O Humbert, Anthony M Brumby, Lee F Willoughby, Tanja Schlosser, Samuel A Manning, John P Parisot, Ian P Street, Helena E Richardson, Patrick O Humbert, Anthony M Brumby
Abstract
Anti-cancer drug development involves enormous expenditure and risk. For rapid and economical identification of novel, bioavailable anti-tumour chemicals, the use of appropriate in vivo tumour models suitable for large-scale screening is key. Using a Drosophila Ras-driven tumour model, we demonstrate that tumour overgrowth can be curtailed by feeding larvae with chemicals that have the in vivo pharmacokinetics essential for drug development and known efficacy against human tumour cells. We then develop an in vivo 96-well plate chemical screening platform to carry out large-scale chemical screening with the tumour model. In a proof-of-principle pilot screen of 2000 compounds, we identify the glutamine analogue, acivicin, a chemical with known activity against human tumour cells, as a potent and specific inhibitor of Drosophila tumour formation. RNAi-mediated knockdown of candidate acivicin target genes implicates an enzyme involved in pyrimidine biosynthesis, CTP synthase, as a possible crucial target of acivicin-mediated inhibition. Thus, the pilot screen has revealed that Drosophila tumours are glutamine-dependent, which is an emerging feature of many human cancers, and has validated the platform as a powerful and economical tool for in vivo chemical screening. The platform can also be adapted for use with other disease models, thus offering widespread applications in drug development.
Figures
References
- Agrawal N., Pallos J., Slepko N., Apostol B. L., Bodai L., Chang L. W., Chiang A. S., Thompson L. M., Marsh J. L. (2005). Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. USA 102, 3777-3781
- Ahluwalia G. S., Grem J. L., Hao Z., Cooney D. A. (1990). Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 46, 243-271
- Aritakula A., Ramasamy A. (2008). Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway. J. Biosci. 33, 731-742
- Barrett S. D., Bridges A. J., Dudley D. T., Saltiel A. R., Fergus J. H., Flamme C. M., Delaney A. M., Kaufman M., LePage S., Leopold W. R., et al. (2008). The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 18, 6501-6504
- Brumby A. M., Richardson H. E. (2003). scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila. EMBO J. 22, 5769-5779
- Brumby A. M., Richardson H. E. (2005). Using Drosophila melanogaster to map human cancer pathways. Nat. Rev. Cancer 5, 626-639
- Chang S., Bray S. M., Li Z., Zarnescu D. C., He C., Jin P., Warren S. T. (2008). Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256-263
- Chen K., Zhang J., Tastan O. Y., Deussen Z. A., Siswick M. Y., Liu J. L. (2011). Glutamine analogs promote cytoophidium assembly in human and Drosophila cells. J. Genet. Genomics 38, 391-402
- Colombani J., Andersen D. S., Leopold P. (2012). Secreted peptide Dilp8 coordinates Drosophila tissue growth with developmental timing. Science 336, 582-585
- Cordero J. B., Macagno J. P., Stefanatos R. K., Strathdee K. E., Cagan R. L., Vidal M. (2010). Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev. Cell 18, 999-1011
- Dar A. C., Das T. K., Shokat K. M., Cagan R. L. (2012). Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80-84
- DeBerardinis R. J., Cheng T. (2010). Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324
- Denton J. E., Lui M. S., Aoki T., Sebolt J., Weber G. (1982). Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatoma. Life Sci. 30, 1073-1080
- Earhart R. H., Neil G. L. (1985). Acivicin in 1985. Adv. Enzyme Regul. 24, 179-205
- Edwards A., Gladstone M., Yoon P., Raben D., Frederick B., Su T. T. (2011). Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis. Model. Mech. 4, 496-503
- Ellims P. H., Gan T. E., Medley G. (1983). Cytidine triphosphate synthetase activity in lymphoproliferative disorders. Cancer Res. 43, 1432-1435
- Garelli A., Gontijo A. M., Miguela V., Caparros E., Dominguez M. (2012). Imaginal discs secrete insulin-like peptide 8 to mediate plasticity of growth and maturation. Science 336, 579-582
- Gladstone M., Su T. T. (2011). Chemical genetics and drug screening in Drosophila cancer models. J. Genet. Genomics 38, 497-504
- Goebel M. (1993). Oral idarubicin - an anthracycline derivative with unique properties. Ann. Hematol. 66, 33-43
- Jayaram H. N., Cooney D. A., Ryan J. A., Neil G., Dion R. L., Bono V. H. (1975). L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother. Rep. 59, 481-491
- Kang H. L., Benzer S., Min K. T. (2002). Life extension in Drosophila by feeding a drug. Proc. Natl. Acad. Sci. USA 99, 838-843
- Kizaki H., Williams J. C., Morris H. P., Weber G. (1980). Increased cytidine 5- triphosphate synthetase activity in rat and human tumors. Cancer Res. 40, 3921-3927
- McBride S. M., Choi C. H., Wang Y., Liebelt D., Braunstein E., Ferreiro D., Sehgal A., Siwicki K. K., Dockendorff T. C., Nguyen H. T., et al. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45, 753-764
- McPartland R. P., Wang M. C., Bloch A., Weinfeld H. (1974). Cytidine 5- triphosphate synthetase as a target for inhibition by the antitumor agent 3- deazauridine. Cancer Res. 34, 3107-3111
- Moreadith R. W., Lehninger A. L. (1984). The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J. Biol Chem. 259, 6215-6221
- Pagliarini R. A., Xu T. (2003). A genetic screen in Drosophila for metastatic behavior. Science 302, 1227-1231
- Pandey U. B., Nichols C. D. (2011). Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 63, 411-436
- Pastor-Pareja J. C., Wu M., Xu T. (2008). An innate immune response of blood cells to tumors and tissue damage in Drosophila. Dis. Model. Mech. 1, 144-154
- Shah S., Yarrow C., Dunning R., Cheek B., Vass S., Windass J., Hadfield S. (2012). Insecticide detoxification indicator strains as tools for enhancing chemical discovery screens. Pest Manag. Sci. 68, 38-48
- Stilwell G. E., Saraswati S., Littleton J. T., Chouinard S. W. (2006). Development of a Drosophila seizure model for in vivo high-throughput drug screening. Eur. J. Neurosci. 24, 2211-2222
- Ursprung H. (1967). In vivo culture of Drosophila imaginal discs. In Methods in Developmental Biology (ed. Wilt F. H., Wessells N. K.), pp. 485-492 New York, NY: Thomas Y. Cromwell Company
- Vidal M., Wells S., Ryan A., Cagan R. (2005). ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65, 3538-3541
- Willecke M., Toggweiler J., Basler K. (2011). Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model. Oncogene 30, 4067-4074
- Williams J. C., Kizaki H., Weber G., Morris H. P. (1978). Increased CTP synthetase activity in cancer cells. Nature 271, 71-73
- Wise D. R., Thompson C. B. (2010). Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427-433
- Zhang J. H., Chung T. D., Oldenburg K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73
Source: PubMed